Zacks: Analysts Expect CytomX Therapeutics, Inc. (CTMX) Will Announce Quarterly Sales of $10.70 Million

Analysts expect that CytomX Therapeutics, Inc. (NASDAQ:CTMX) will announce sales of $10.70 million for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for CytomX Therapeutics’ earnings, with estimates ranging from $600,000.00 to $16.50 million. CytomX Therapeutics posted sales of $6.27 million in the same quarter last year, which suggests a positive year-over-year growth rate of 70.7%. The company is scheduled to issue its next earnings results on Thursday, March 1st.

On average, analysts expect that CytomX Therapeutics will report full-year sales of $10.70 million for the current fiscal year, with estimates ranging from $45.20 million to $61.00 million. For the next financial year, analysts forecast that the company will report sales of $79.53 million per share, with estimates ranging from $60.00 million to $104.60 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow CytomX Therapeutics.

Several equities analysts have recently commented on the stock. Zacks Investment Research cut shares of CytomX Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday. Cantor Fitzgerald assumed coverage on shares of CytomX Therapeutics in a research report on Monday, October 23rd. They issued an “overweight” rating and a $35.00 target price for the company. Cowen and Company reiterated an “outperform” rating on shares of CytomX Therapeutics in a research report on Thursday, October 5th. Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of CytomX Therapeutics in a research report on Wednesday, October 4th. Finally, Bank of America Corporation upped their price objective on shares of CytomX Therapeutics from $30.00 to $34.00 and gave the stock a “buy” rating in a research report on Wednesday, October 4th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and seven have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $31.88.

CytomX Therapeutics (NASDAQ CTMX) traded up $0.18 during midday trading on Friday, reaching $19.93. 643,100 shares of the company’s stock were exchanged, compared to its average volume of 270,510. CytomX Therapeutics has a 52-week low of $10.03 and a 52-week high of $24.67.

In related news, CEO Sean A. Mccarthy sold 14,342 shares of the firm’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $19.86, for a total value of $284,832.12. Following the sale, the chief executive officer now directly owns 18,587 shares of the company’s stock, valued at $369,137.82. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider William Michael Kavanaugh sold 48,368 shares of the firm’s stock in a transaction that occurred on Wednesday, October 4th. The shares were sold at an average price of $24.34, for a total transaction of $1,177,277.12. The disclosure for this sale can be found here. Insiders have sold 187,355 shares of company stock valued at $4,031,706 in the last 90 days. 8.00% of the stock is currently owned by corporate insiders.

A number of large investors have recently added to or reduced their stakes in CTMX. Legal & General Group Plc boosted its holdings in shares of CytomX Therapeutics by 28.6% during the 2nd quarter. Legal & General Group Plc now owns 6,448 shares of the biotechnology company’s stock valued at $101,000 after buying an additional 1,434 shares in the last quarter. Macquarie Group Ltd. purchased a new position in shares of CytomX Therapeutics in the 3rd quarter worth about $107,000. First Quadrant L P CA purchased a new position in shares of CytomX Therapeutics in the 2nd quarter worth about $160,000. Cubist Systematic Strategies LLC purchased a new position in CytomX Therapeutics in the 2nd quarter worth about $174,000. Finally, Goldman Sachs Group Inc. purchased a new position in CytomX Therapeutics in the 1st quarter worth about $190,000. Institutional investors and hedge funds own 57.85% of the company’s stock.

TRADEMARK VIOLATION WARNING: This news story was reported by Markets Daily and is owned by of Markets Daily. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of United States and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.themarketsdaily.com/2017/11/15/zacks-analysts-expect-cytomx-therapeutics-inc-ctmx-will-announce-quarterly-sales-of-10-70-million.html.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.

Get a free copy of the Zacks research report on CytomX Therapeutics (CTMX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply